APA (7th ed.) Citation

Meindl-Beinker, N. M., Betge, J., Gutting, T., Burgermeister, E., Belle, S., Zhan, T., . . . Härtel, N. (2019). A multicenter open-label phase II trial to evaluate nivolumab and ipilimumab for 2nd line therapy in elderly patients with advanced esophageal squamous cell cancer (RAMONA). BioMed Central ; Springer. https://doi.org/https://doi.org/10.1186/s12885-019-5446-2

Chicago Style (17th ed.) Citation

Meindl-Beinker, Nadja M., Johannes Betge, Tobias Gutting, Elke Burgermeister, Sebastian Belle, Tianzuo Zhan, Nadine Schulte, Matthias Ebert, and Nicolai Härtel. A Multicenter Open-label Phase II Trial to Evaluate Nivolumab and Ipilimumab for 2nd Line Therapy in Elderly Patients with Advanced Esophageal Squamous Cell Cancer (RAMONA). London ; Berlin, Heidelberg: BioMed Central ; Springer, 2019. https://doi.org/https://doi.org/10.1186/s12885-019-5446-2.

MLA (9th ed.) Citation

Meindl-Beinker, Nadja M., et al. A Multicenter Open-label Phase II Trial to Evaluate Nivolumab and Ipilimumab for 2nd Line Therapy in Elderly Patients with Advanced Esophageal Squamous Cell Cancer (RAMONA). BioMed Central ; Springer, 2019. https://doi.org/https://doi.org/10.1186/s12885-019-5446-2.